Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia
Status:
Active, not recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
In Waldenström macroglobulinemia (WM) conventional chemotherapy induces only low CR rates and
responses of short duration compared to other indolent lymphomas. Thus innovative approaches
are needed which combine excellent activity and tolerability in patients with WM, who are
mostly of advanced age. The immunochemotherapy DRC (dexamethasone, rituximab,
cyclophosphamide) was shown to be highly effective in patients with WM without inducing major
hematological toxicities. On the other hand the proteasome inhibitor Bortezomib showed
substantial activity as a single agent in WM with only very few side effects when given in a
weekly schedule. Based on these observations it is the aim of this study to test whether the
efficacy of the well tolerated DRC regime can be further improved by adding Bortezomib.
Phase:
Phase 3
Details
Lead Sponsor:
University of Ulm
Collaborator:
Centre Hospitalier de Lens, Unité de Recherche Clinique, Lens (Co-Sponsor)